Personalis, Inc. - 8-K Filing
Personalis reported Q1 2026 results with revenue of $15.5 million, a decline from $20.6 million in Q1 2025, driven by a planned reduction in non-core revenue. Clinical test volume surged 258% YoY to 7,815 tests, generating $1.4 million in clinical revenue. The company secured Medicare coverage for lung cancer surveillance and reaffirmed full-year guidance for clinical test volume of 43,000–45,000 tests and clinical revenue of $10.0–$11.0 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PSNL